Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) announced that Mark A. Goldsmith, M.D., Ph.D., CEO and chairman, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET.

According to the company, the session will be webcast live and a replay will be available on the company's investor website for at least 14 days following the event.

Key Figures

Summit date: February 11, 2026 Fireside chat time: 9:30 a.m. ET Webcast replay window: 14 days

3 metrics

Summit date February 11, 2026 Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Fireside chat time 9:30 a.m. ET Scheduled time for CEO participation at Guggenheim Summit

Webcast replay window 14 days Replay available on company website after live webcast

Market Reality Check

Price: $96.51 Vol: Volume 2,414,333 is below...

low vol

$96.51 Last Close

Volume Volume 2,414,333 is below 20-day average 5,705,690 (relative volume 0.42). low

Technical Price 95.97 is trading above 200-day MA at 54.98, indicating prior uptrend strength.

Peers on Argus

RVMD fell 1.22% while close peers showed mixed, mostly small moves (e.g., BPMC +...

1 Down

RVMD fell 1.22% while close peers showed mixed, mostly small moves (e.g., BPMC +0.09%, MRNA -1.06%). This points to stock-specific action rather than a broad biotech move.

Historical Context

5 past events · Latest: Jan 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 29	Clinical trial start	Positive	+0.9%	First patient dosed in RMC-5127-001 first-in-human trial.
Jan 08	Regulatory designation	Positive	+4.6%	FDA Breakthrough Therapy Designation for zoldonrasib in KRAS G12D NSCLC.
Jan 05	Conference participation	Positive	+1.9%	J.P. Morgan Healthcare Conference presentation and webcast availability.
Dec 18	Phase 3 trial progress	Positive	-1.0%	First patient randomized in Phase 3 RASolute 304 daraxonrasib trial.
Nov 05	Earnings and pipeline	Positive	+1.3%	Q3 2025 results with RASolute program updates and strong cash balance.

Pattern Detected

Recent news, especially clinical and regulatory milestones, has typically seen RVMD trade higher, with only one negative reaction among the last five items.

Recent Company History

Over the past few months, RVMD has reported multiple clinical and regulatory milestones, including first patient dosing in RMC-5127-001 on Jan 29, 2026, FDA Breakthrough Therapy Designation for zoldonrasib on Jan 8, 2026, and Phase 3 RASolute 304 randomization on Dec 18, 2025. Q3 2025 results on Nov 5, 2025 highlighted cash and marketable securities of $1.93B. Prior conference participation, such as the 44th J.P. Morgan event on Jan 12, 2026, also saw a positive price reaction, similar in nature to today’s Guggenheim conference announcement.

Market Pulse Summary

This announcement highlights RVMD’s participation in the Guggenheim Emerging Outlook: Biotech Summit...

Analysis

This announcement highlights RVMD’s participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, offering another venue for management to communicate its late-stage oncology strategy. Recent history includes key milestones like Breakthrough Therapy Designation for zoldonrasib and initiation of the RASolute 304 Phase 3 trial, supported by a reported cash balance of $1.93B as of Q3 2025. Investors may watch upcoming trial readouts, regulatory updates, and further conference appearances for incremental signals.

AI-generated analysis. Not financial advice.

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET.

To listen to a live webcast of this event, or access an archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact: 
media@revmed.com
investors@revmed.com 

FAQ

When will Revolution Medicines (RVMD) present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026?

The CEO will speak on Wednesday, February 11, 2026 at 9:30 a.m. ET in a fireside chat. According to the company, this session is part of the Guggenheim Emerging Outlook: Biotech Summit 2026 and is scheduled as a live webcast.

How can investors watch the RVMD webcast and where will the replay be posted?

Investors can watch the live webcast and access an archived replay on the company's investor website. According to the company, visit the events and presentations page; a replay will remain available for at least 14 days after the live event.

Who from Revolution Medicines (RVMD) will participate in the fireside chat and what is their role?

Mark A. Goldsmith, M.D., Ph.D., CEO and chairman of RVMD, will participate in the fireside chat and speak about company matters. According to the company, he will represent the firm and discuss its late-stage clinical oncology programs focused on RAS-addicted cancers.

Will Revolution Medicines (RVMD) present new clinical trial data at the February 11, 2026 session?

The announcement does not state that new clinical data will be presented at the session on February 11, 2026. According to the company, the notice confirms CEO participation and live webcast access; viewers should consult the webcast for any disclosures.

How long will the Revolution Medicines (RVMD) webcast replay remain available after the Guggenheim summit?

The replay will be available on the company's website for at least 14 days after the live webcast. According to the company, the archived webcast is accessible via the events and presentations page within that minimum availability window.